1. Milar S, Stone N, Yates A, O’Sullivan S. A systematic review of the pharmacokinetics of cannabidiol in humans. Frontiers in Pharma 26 Nov 2018
2. Jiang R, Yamaori S, Takeda S, Yamamoto I, Watanabe K. Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes. Life Sciences 89 (2011) 165-170
3. Zendulka O, Dovrelova G, Noskova K, Turjap M, Sulcova A, Hanus L, Jurica J. Cannabinoids and Cytochrome P450 Interactions. Curr Drug Metab 2016;17(3):206-26
4. Rajinder K. Bhardwaj, Hartmut Glaeser, Laurent Becquemont, Ulrich Klotz, Suresh K. Gupta and Martin F. Fromm. Piperine. A Major Constituent of Black Pepper, Inhibits Human P-glycoprotein and CYP3A4. J Pharmacol Exp Ther. August 2002, 302 (2) 645-650
5. Volak L, Ghirmai S, Cashman J, and Court M. Curcuminoids inhibit multiple human cytochromes P450 (CYP), UDP-glucuronosyltransferase (UGT), and sulfotransferase (SULT) enzymes, while piperine is a relatively selective CYP3A4 inhibitor. Drug Metab Dispos. 2008 Aug; 36(8): 1594–1605.
6. Ho P C, Saville D J, Coville P F, Wanwimolruk S. Content of CYP3A4 Inhibitors, Naringin, Naringenin and Bergapten in Grapefruit and Grapefruit Juice Products. Pharm Acta Helv. 2000 Apr;74(4):379-85.
7. Fasinu P, Choonara Y, Khan R, Du Toit L C, Kumar P, Ndesendo V, Pillay V. Flavonoids and Polymer Derivatives as CYP3A4 Inhibitors for Improved Oral Drug Bioavailability. J Pharm Sci . 2013 Feb;102(2):541-55.
8. Wadhwa S, Singhal S, Rawat S. Bioavailability Enhancement by Piperine: A Review. Asian J Biomed & Pharm Sciences. Vol 4, Issue 36, 2014.